LabCorp Extends Proposed Orchid Cellmark Buy Again | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today announced it is further extending its cash tender offer for Orchid Cellmark as it continues to provide answers to questions about the deal to the US Federal Trade Commission.

The $85.4 million proposed deal, announced in April, has been extended to 5 p.m. EDT, Nov. 14. It was previously extended to Nov. 4, and now has been extended eight times.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.